The Burrill Report


The Burrill Report (December 5, 2011): Why Pfizer Might Have Been Better Off Without Lipitor (.MP3,14.3 Mb)

Pfizer’s blockbuster Lipitor, the best-selling drug of all time, has now gone off-patent. The expiration of the patent marks the end of an era where the blockbuster defined the pharmaceutical industry. But it also raises some interesting questions about the way pharmaceutical companies develop and sell drugs, as well as the wisdom of making big acquisitions. We spoke to Chris Bowe, U.S. healthcare analyst for Scrip, about the lessons from Lipitor, whether it was a triumph of science or marketing, and why Pfizer might have been better off without it.


December 02, 2011
http://www.burrillreport.com/article-why_pfizer_might_have_been_better_off_without_lipitor.html